AstraZeneca releases update on FluMist vaccine
Officials of the Advisory Committee on Immunization Practices (ACIP), under the Centers for Disease Control and Prevention (CDC), stated that FluMist Quadrivalent Live Attenuated Influenza Vaccine can be used in the U.S. during the 2016-17 influenza season.
The recommendations specify that the vaccine is not appropriate for every setting. This is founded on the CDC’s effectiveness data concerning vaccines during the past three influenza seasons. At that time, FluMist did not show that it had notable efficiency for children between two and 17 years old.
CDC data were taken from the 2015-16 influenza season, but studies from AstraZeneca show that the vaccine is effective. Other nations have also conducted preliminary independent studies with public health authorities, and they have found that FluMist is 46 to 58 percent effective in fighting the circulating influenza strains in the 2015-16 season.
Unfortunately, the effectiveness of the influenza vaccine can vary between seasons because the influenza virus is different each season. This is why the vaccine must go through annual observational studies to determine its effectiveness.
Organizations in this story
AstraZeneca Pharmaceuticals LP 1800 Concord Pike Wilmington, DE 19803